test

This assay is a cytogenetic technique employed to detect the presence of the Philadelphia chromosome, a hallmark of chronic myelogenous leukemia (CML) and some acute lymphoblastic leukemias (ALL). The procedure utilizes fluorescently labeled DNA probes that bind to specific regions of the BCR and ABL1 genes. When these genes fuse due to a chromosomal translocation, the probes will appear closer together under a fluorescence microscope, signaling the presence of the fusion gene. For instance, in a normal cell, two distinct signals for BCR and ABL1 would be observed, whereas in a cell with the translocation, a single, fused signal is evident.

The clinical relevance of this diagnostic tool lies in its ability to confirm a CML diagnosis, monitor treatment response, and detect minimal residual disease. Early and accurate detection of the BCR-ABL1 fusion transcript allows for timely initiation of targeted therapies, such as tyrosine kinase inhibitors (TKIs), significantly improving patient outcomes. Historically, other methods like karyotyping were used; however, this method offers greater sensitivity and speed, particularly useful in assessing treatment efficacy and detecting relapse earlier than other conventional cytogenetic methods.

Read more